BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 29770131)

  • 1. Real-Time Tracking of
    Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
    Front Immunol; 2018; 9():825. PubMed ID: 29770131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo.
    Uong TNT; Yoon MS; Lee KH; Hyun H; Nam TK; Min JJ; Nguyen HPQ; Kim SK
    Cytotherapy; 2021 Sep; 23(9):799-809. PubMed ID: 34176769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.
    Shenouda MM; Gillgrass A; Nham T; Hogg R; Lee AJ; Chew MV; Shafaei M; Aarts C; Lee DA; Hassell J; Bane A; Dhesy-Thind S; Ashkar AA
    Breast Cancer Res; 2017 Jul; 19(1):76. PubMed ID: 28668076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model.
    Kim KW; Jeong JU; Lee KH; Uong TNT; Rhee JH; Ahn SJ; Kim SK; Cho D; Quang Nguyen HP; Pham CT; Yoon MS
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):115-125. PubMed ID: 31605787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
    Mimura K; Kamiya T; Shiraishi K; Kua LF; Shabbir A; So J; Yong WP; Suzuki Y; Yoshimoto Y; Nakano T; Fujii H; Campana D; Kono K
    Int J Cancer; 2014 Sep; 135(6):1390-8. PubMed ID: 24615495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.
    Nham T; Poznanski SM; Fan IY; Vahedi F; Shenouda MM; Lee AJ; Chew MV; Hogg RT; Lee DA; Ashkar AA
    J Immunother; 2018; 41(2):64-72. PubMed ID: 29189387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Tracking of Cell Viability for Adoptive Natural Killer Cell-Based Immunotherapy by Ratiometric NIR-II Fluorescence Imaging.
    Liao N; Su L; Zheng Y; Zhao B; Wu M; Zhang D; Yang H; Liu X; Song J
    Angew Chem Int Ed Engl; 2021 Sep; 60(38):20888-20896. PubMed ID: 34268865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.
    Oyer JL; Pandey V; Igarashi RY; Somanchi SS; Zakari A; Solh M; Lee DA; Altomare DA; Copik AJ
    Cytotherapy; 2016 May; 18(5):653-63. PubMed ID: 27059202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells.
    Vahedi F; Nham T; Poznanski SM; Chew MV; Shenouda MM; Lee D; Ashkar AA
    Sci Rep; 2017 Sep; 7(1):12083. PubMed ID: 28935883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
    Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
    Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.